Timing of selective serotonin reuptake inhibitor use and risk for preterm birth and related adverse events: with a consideration of the COVID-19 pandemic period.
Publication Title
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
Document Type
Article
Publication Date
12-1-2024
Keywords
Pregnancy; Infant; Infant, Newborn; Humans; Female; Selective Serotonin Reuptake Inhibitors; Premature Birth; Pandemics; Pregnancy Complications; COVID-19; Fetal Growth Retardation; Infant, Newborn, Diseases; wasghinton; isb; renton
Abstract
OBJECTIVE: There is uncertainty around the safety of SSRIs for treating depression during pregnancy. Nevertheless, the use of SSRIs has been gradually increasing, especially during the COVID-19 pandemic period. We aimed to (1) characterize maternal depression rate and use of SSRIs in a recent 10-year period, (2) address confounding by indication, as well as socioeconomic and environmental factors, and (3) evaluate associations of the timing of SSRI exposure in pregnancy with risk for preterm birth (PTB), low birthweight (LBW), and small for gestational age (SGA) infants among women with depression before pregnancy.
METHODS: We conducted propensity score-adjusted regression to calculate odds ratios (ORs) of PTB, LBW, and SGA. We accounted for maternal/pregnancy characteristics, comorbidity, depression severity, time of delivery, social vulnerability, and rural residence.
RESULTS: There were 50.3% and 40.3% increases in the prevalence rate of prenatal depression and prenatal SSRI prescription rate during the pandemic. We identified women with depression ?180 days before pregnancy (
CONCLUSIONS: These findings suggest an association between PTB/LBW and SSRI exposure is dependent on exposure timing during pregnancy. Small for gestational age is not associated with SSRI exposure.
Clinical Institute
Mental Health
Clinical Institute
Women & Children
Specialty/Research Institute
Obstetrics & Gynecology
Specialty/Research Institute
Pharmacy
Specialty/Research Institute
Infectious Diseases
DOI
10.1080/14767058.2024.2313364
